Abstract
Although the incidence of rheumatic fever has declined dramatically in developed countries in the last few decades, it continues to be a major cause of morbidity and mortality in the developing world. There is no test specific for the diagnosis in rheumatic fever, and the diagnosis relies heavily on clinical findings and a few simple investigations.
Those with a history of or established rheumatic fever are at increased risk of recurrence, and thus, a lower threshold for the diagnosis of recurrence has been established. Secondary prophylaxis has proven to be the most cost-effective strategy for the prevention of recurrence. Especially in high-risk settings and in more severe valvular heart disease, a longer period, in some cases even lifelong, of prophylaxis is advocated according to the new WHO guidelines.
Mitral stenosis is almost exclusively due to rheumatic heart disease. Medical management, percutaneous balloon valvuloplasty, and valve replacement strategies are discussed. Pure MR is uncommon in rheumatic heart disease. Mitral valve repair or replacement is indicated in patients with severe MR and NYHA III or IV. Asymptomatic or mildly symptomatic patients can be managed medically provided LVEF and symptoms get monitored, and they are referred for surgery if the EF falls toward 60 % or the end-systolic dimension reaches 45 mm.
Aortic stenosis requires surgery when symptoms occur. Patients with severe aortic regurgitation should also be offered valve replacement when they become symptomatic. Those with severe AR who do not experience symptoms require careful evaluation and follow-up of their left ventricular ejection fractions and end-systolic and end-diastolic diameters to determine when surgery would be warranted.
Tricuspid disease is often overlooked as the symptoms of the left-sided lesion may predominate. It is almost always associated with mitral valve disease and adds a dimension of complexity to the treatment as well as an unfavorable impact on prognosis.
In many cases multiple valves are involved, and this has a profound impact on the assessment, by any modality, of the severity of each individual valve lesion.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sliwa K et al. Incidence and characteristics of newly diagnosed RHD in urban African adults: insights from the heart of Soweto study. Eur Heart J. 2010;31:719–27.
Marijon E et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007;357(5):470–6.
Siegel AC, Johnson EE, Stollerman GH. Controlled studies of streptococcal pharyngitis in a pediatric population. 1. Factors related to the attack rate of rheumatic fever. N Engl J Med. 1961;265:559–65.
Dale JB, Beachey EH. Sequence of myosin cross-reactive epitopes of streptococcal M protein. J Exp Med. 1986;164:1785–90.
Haffejee I. Rheumatic fever and rheumatic heart disease: the current state of its immunology, diagnostic criteria and prophylaxis. Q J Med. 1992;84:641–58.
Jones TD. Diagnosis of rheumatic fever. JAMA. 1944;126:481–4.
Dajani AS, Ayoub EM, Bierman FZ, et al. Guidelines for the diagnosis of rheumatic fever: Jones criteria, updated 1992. JAMA. 1992;268:2069–73.
Carapetis J et al. Acute rheumatic fever. Lancet. 2005;366:155–68.
Dajani AS. Current status of nonsuppurative complications of group A streptococci. Pediatr Infect Dis J. 1991;10:S25–7.
2002–2003 Criteria for recurrent rheumatic fever. WHO: Rheumatic fever and Rheumatic heart disease: report of a WHO expert consultation. Geneva: WHO; 2004.
Haskes PJ et al. Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomised control trial. J Pediatr. 2003;143:300–401.
Albert DA, Harel L, Karrison T. The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore). 1995;74:1–12.
Cilliers AM, et al. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev. 2003;(2):CD003176.
Lewis BS, Geft IL, Milo S, Gotsman MS. Echocardiography and valve replacement in the critically ill patient with acute rheumatic carditis. Ann Thorac Surg. 1979;27:529–35.
WHO technical report series. Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation. Geneva. 29 Oct–1 Nov 2001.
Lue HC, Wu MH, Wang JK, et al. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr. 1994;125:812–6.
Hu MC, Walls MA, Stroop SD, et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun. 2002;70:2171–7.
Olson LJ, Subramanian R, Ackermann DM, et al. Surgical pathology of the mitral valve. A study of 712 cases spanning 21 years. Mayo Clin Proc. 1987;62:22–34.
Leavitt JI, Coats MH, Falk RH. Effects of exercise on transmitral gradient and pulmonary artery pressure in patients with mitral stenosis or a prosthetic mitral valve. A Doppler echocardiographic study. J Am Coll Cardiol. 1991;17:1520–6.
Ohmichi M, Tagaki S, Nomura N, et al. Endobronchial changes in chronic pulmonary venous hypertension. Chest. 1988;94:1127–32.
Barrington WW, Boudoulas J, Bashore T, et al. Mitral stenosis: mitral dome excursion at M1 and the mitral opening snap—the concept of reciprocal heart sounds. Am Heart J. 1998;115:1280–90.
Chiang CW et al. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med. 1998;128:885.
Salem DN et al. American College of Chest Physicians Evidenced-based Clinical Practice Guidelines 8th edition. Valvular and structural heart disease. Chest. 2008;133:593S–629.
Klein HO, Sareli P, Schamroth CL, et al. Effects of atenolol on exercise capacity in patients with mitral stenosis with sinus rhythm. Am J Cardiol. 1985;56:598–601.
Stoll BC et al. Effects of atenolol on rest and exercise haemodynamics in patients with mitral stenosis. Am J Cardiol. 1995;75:482.
Bonow RO, Carabello B, de Leon Jr AC, et al. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation. 2006;114:e84–231.
Marcus RH, Sareli P, Pocock WA, Barlow JB. The spectrum of severe rheumatic mitral valve disease in a developing country: correlations among clinical presentations, surgical pathologic finding and haemodynamic sequelae. Ann Intern Med. 1994;120:177–83.
Carabello BA, Crawford FA. Valvular heart disease. N Engl J Med. 1997;337:32–41.
Rahimtoola SH. Valvular heart disease: a perspective. J Am Coll Cardiol. 1983;1:199–215.
Passik CS, Ackermann DM, Pluth JR, Edwards WP. Temporal changes in the causes of aortic stenosis: a surgical pathologic study of 646 cases. Mayo Clin Proc. 1987;62:119–23.
Levinson GE. Aortic stenosis. In: Dalen JE, Alpert JS, editors. Valvular heart disease. 2nd ed. Boston: Little, Brown; 1987. p. 202–3.
Zitnik RS, Piemme TE, Messer RJ, et al. The masking of aortic stenosis by mitral stenosis. Am Heart J. 1965;69:22–30.
Ross Jr J, Braunwald E. Aortic stenosis. Circulation. 1968;38(Suppl V):V-61–7.
Lancellotti P et al. Clinical outcome in asymptomatic severe aortic stenosis. J Am Coll Cardiol. 2012;59:235–43.
Flachskampf FA et al. Varying haemodynamics and differences in prognosis in patients with asymptomatic severe aortic stenosis and preserved ejection function: a call to review cutoffs and concepts. J Am Coll Cardiol. 2012;59:244–5.
Awtry E, Davidhoff R, et al. Low flow/low gradient aortic stenosis. Circulation. 2011;124:e739–41.
Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994;331:689–94.
Rahimtoola SH. Indications for surgery in aortic valve disease. In: Yusuf S, Cairns JA, Camm AJ, editors. Evidence based cardiology. London: BMJ Books; 1998. p. 811–32.
Braunwald E. Valvular heart disease. In: Braunwald EB, editor. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: W. B. Saunders; 1997. p. 1007–76.
Unger P, Rosenhek R, Deeobbeleer A, et al. Management of multiple valve disease. Heart. 2011;97:272–7.
Recommended Reading
Carabello BA. Mitral valve disease: indications for surgery. In: Yusuf S, Cairns JA, Camm AJ, editors. Evidence based cardiology. London: BMJ Books; 2003. p. 758–66.
Dajani A, Taubert K, Ferrieri P, et al. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Pediatrics. 1995;96:758–64.
Otto CM, Burwask IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997;95:2262–70.
Turi ZG. Balloon valvuloplasty: mitral valve. In: Yusuf S, Cairns JA, Camm AJ, editors. Evidence based cardiology. London: BMJ Books; 2003. p. 796–808.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cupido, B.J., Commerford, P.J. (2013). Rheumatic Fever and Valvular Heart Disease. In: Rosendorff, C. (eds) Essential Cardiology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6705-2_29
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6705-2_29
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6704-5
Online ISBN: 978-1-4614-6705-2
eBook Packages: MedicineMedicine (R0)